MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.06 -1.29

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.06

Max

3.09

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+30.29% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-36M

1.1B

Vorige openingsprijs

4.35

Vorige sluitingsprijs

3.06

Nieuwssentiment

By Acuity

50%

50%

185 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 17:04 UTC

Belangrijke Marktbewegers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 apr 2026, 00:00 UTC

Winsten
Acquisities, Fusies, Overnames

Big Yachts, Big Bucks -- Barrons.com

10 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 apr 2026, 21:01 UTC

Winsten

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 20:31 UTC

Marktinformatie

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 apr 2026, 20:10 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 19:15 UTC

Marktinformatie

Global Energy Roundup: Market Talk

10 apr 2026, 19:15 UTC

Marktinformatie

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 apr 2026, 18:38 UTC

Marktinformatie

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 apr 2026, 18:25 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Precious Metals Finish With Weekly Gains -- Market Talk

10 apr 2026, 18:05 UTC

Marktinformatie

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 apr 2026, 17:31 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 apr 2026, 17:26 UTC

Winsten

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 apr 2026, 17:10 UTC

Marktinformatie

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 apr 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 apr 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

10 apr 2026, 16:12 UTC

Winsten

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 apr 2026, 16:11 UTC

Winsten

Partners Group: Traditional Programs Contributed $3.3B

10 apr 2026, 16:10 UTC

Winsten

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 apr 2026, 16:10 UTC

Winsten

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 apr 2026, 16:10 UTC

Winsten

Partners Group 1Q New Client Demand $8.3B

10 apr 2026, 16:09 UTC

Winsten

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 apr 2026, 15:54 UTC

Acquisities, Fusies, Overnames

Plenitude Completes Acquisition of Acea Energia

10 apr 2026, 15:38 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

30.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  30.29%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

185 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat